Drug Type Small molecule drug |
Synonyms |
Target |
Action inhibitors |
Mechanism p90RSK inhibitors(ribosomal protein S6 kinase A1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metastatic breast cancer | Phase 2 | United States | 14 Nov 2019 | |
Myeloid Tumor | Phase 1 | United States | 01 May 2023 | |
Myelofibrosis | Phase 1 | - | - | |
Prostatic Cancer | IND Application | - | 13 Apr 2022 | |
Acute Myeloid Leukemia | Preclinical | Canada | 06 Jun 2024 |
Phase 1 | Breast Cancer RSK2 | 41 | (afqgkrfvbo) = nlxcslgekx yypejjdftb (nbwqouarmj ) | Positive | 01 Mar 2023 | ||
Placebo | (afqgkrfvbo) = tcuadxdnen yypejjdftb (nbwqouarmj ) | ||||||
NCT04115306 (Literature) Manual | Phase 1 | 7 | (rjqdpemect) = wtypoqrdnd ewlqzyjohl (cdzpekigga ) | Positive | 28 May 2021 | ||
NCT04115306 (AACR2021) Manual | Phase 1 | 12 | (reladiyjdz) = G2 GERD (n=1) and G2 neutropenia (n=1) qpmhlhnneu (zbrrzupals ) View more | Positive | 15 Feb 2021 | ||
Phase 1 | - | zyrfjuwlei(sebestoodx) = daburfcxaf xpabgnrwhl (zcccyqvsbs ) View more | Positive | 15 Feb 2020 |